ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.102,33
-0,33%
S&P 500
5.469,30
0,00%
Dow Jones
39.112,16
0,00%
Euro vs US Dollar
1,06868
-0,21%
Bitcoin
61.337,45
-0,77%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. Vereinigtes Königreich
  5. LSE
  6. Shield Therapeutics Plc (STX)

  7. Shield Therapeutics Plc (STX) News

STX

Shield Therapeutics (STX)

Shield Therapeutics Plc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:LSE:STX
DatumZeitQuelleÜberschriftSymbolFirma
20/06/202417h25RNS Regulatory NewsShield Therapeutics PLC Results of 2024 Annual General MeetingLSE:STXShield Therapeutics Plc
28/05/202421h32Alliance NewsAlliance NewsTRADING UPDATES: NetScientific backs Wanda; Inspirit Energy wins dealLSE:STXShield Therapeutics Plc
28/05/202408h00RNS Regulatory NewsShield Therapeutics PLC New Drug Application for Accrufer® in South KoreaLSE:STXShield Therapeutics Plc
10/05/202416h30RNS Regulatory NewsShield Therapeutics PLC Audited results for the year ended 31 Dec 2023LSE:STXShield Therapeutics Plc
30/04/202420h54Alliance NewsAlliance NewsEARNINGS AND TRADING: Software Circle & Beximco report higher revenueLSE:STXShield Therapeutics Plc
30/04/202408h00RNS Regulatory NewsShield Therapeutics PLC Business Update for Q1 2024LSE:STXShield Therapeutics Plc
16/04/202408h00RNS Regulatory NewsShield Therapeutics PLC Notice of ResultsLSE:STXShield Therapeutics Plc
21/02/202413h36Alliance NewsAlliance NewsShield Therapeutics sinks as strong performance marred by data issuesLSE:STXShield Therapeutics Plc
21/02/202408h00RNS Regulatory NewsShield Therapeutics PLC Unaudited Full Year Trading UpdateLSE:STXShield Therapeutics Plc
09/01/202412h33Alliance NewsAlliance NewsIN BRIEF: Shield Therapeutics hires former Akili leader as new CFOLSE:STXShield Therapeutics Plc
09/01/202408h00UK RegulatoryShield Therapeutics PLC Appointment of new Chief Financial OfficerLSE:STXShield Therapeutics Plc
07/12/202316h31Alliance NewsAlliance NewsTRADING UPDATES: Comptoir opens restaurant; Intercede wins contractLSE:STXShield Therapeutics Plc
07/12/202308h00UK RegulatoryShield Therapeutics PLC Q3 2023 U.S. Commercial HighlightsLSE:STXShield Therapeutics Plc
27/11/202318h24UK RegulatoryShield Therapeutics PLC PDMR Transaction NotificationLSE:STXShield Therapeutics Plc
20/10/202312h45RNS Non-RegulatoryShield Therapeutics PLC Abstract to be presented at Healthcare ConferenceLSE:STXShield Therapeutics Plc
12/10/202312h14Alliance NewsAlliance NewsIN BRIEF: Shield Therapeutics Chief Financial Officer Rudolf to leaveLSE:STXShield Therapeutics Plc
12/10/202308h00UK RegulatoryShield Therapeutics PLC Chief Financial Officer TransitionLSE:STXShield Therapeutics Plc
03/10/202318h14Alliance NewsAlliance NewsTRADING UPDATES: Aston Martin CEO ups stake; Alkemy's lithium dealLSE:STXShield Therapeutics Plc
03/10/202316h00UK RegulatoryShield Therapeutics PLC Result of REX Retail OfferLSE:STXShield Therapeutics Plc
03/10/202315h29Alliance NewsAlliance NewsShield Therapeutics completes USD20 million SWK financingLSE:STXShield Therapeutics Plc
03/10/202308h00UK RegulatoryShield Therapeutics PLC Completion of SWK FinancingLSE:STXShield Therapeutics Plc
03/10/202308h00UK RegulatoryShield Therapeutics PLC Block listing Interim ReturnLSE:STXShield Therapeutics Plc
28/09/202315h54Alliance NewsAlliance NewsUPDATE: Shield Therapeutics completes GBP5 million share placingLSE:STXShield Therapeutics Plc
28/09/202313h50UK RegulatoryShield Therapeutics PLC Successful completion of US$6.1m Equity FundraiseLSE:STXShield Therapeutics Plc
28/09/202312h30Alliance NewsAlliance NewsShield Therapeutics raises funds for US sales push as loss narrowsLSE:STXShield Therapeutics Plc
28/09/202308h02UK RegulatoryShield Therapeutics PLC REX Retail OfferLSE:STXShield Therapeutics Plc
28/09/202308h01UK RegulatoryShield Therapeutics PLC $20m secured debt facility &proposed equity raiseLSE:STXShield Therapeutics Plc
28/09/202308h00UK RegulatoryShield Therapeutics PLC Interim results update and business updateLSE:STXShield Therapeutics Plc
06/09/202321h33Alliance NewsAlliance NewsIN BRIEF: Shield Therapeutics changes reporting currency to US dollarsLSE:STXShield Therapeutics Plc
06/09/202308h00UK RegulatoryShield Therapeutics PLC Notice of Results and Change in reporting currencyLSE:STXShield Therapeutics Plc
 Showing the most relevant articles for your search:LSE:STX

Kürzlich von Ihnen besucht

AMEX
XLF
Financial Select Sector
AMEX
XLE
Energy Select Sector SPDR
CCOM
US500
US 500
NASDAQ
MSFT
Microsoft
NYSE
KO
Coca Cola
NYSE
JPM
JP Morgan Chase
AMEX
XLV
Health Care Select Sector
NASDAQ
NVDA
NVIDIA
NASDAQ
AMZN
Amazon.com
COIN
SOLUSD
Solana
TG
D7G
Nel ASA
USOTC
ADDYY
Adidas (QX)
TG
432
Arbor Metals
TG
RHM
Rheinmetall
TG
NOV
Novo Nordisk
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten